Brimonidin

Brimonidin
(IUPAC) ime
	5-Bromo-N-(4,5-dihidro-1H-imidazol-2-il) hinoksalin-6-amin
Klinički podaci
Robne marke	Alfagan
AHFS/Drugs.com	Potrošačka informacije o leku
MedlinePlus	a601232
Identifikatori
CAS broj	59803-98-4
ATC kod	S01EA05
PubChem	2435
DrugBank	DB00484
ChemSpider	2341
UNII	E6GNX3HHTE
KEGG	D07540
ChEBI	CHEBI:3175
ChEMBL	CHEMBL844
Hemijski podaci
Formula	C11H10BrN5
Mol. masa	292,135 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17) ; Key: XYLJNLCSTIOKRM-UHFFFAOYSA-N
Farmakokinetički podaci
Metabolizam	Prvenstveno jetra
Poluvreme eliminacije	3 sata
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	℞ Prescription only
Način primene	Okularno, 1 kap

Brimonidin (Alfagan, Alfagan-P) je lek koji se koristi za tretiranje glaukoma ili okularne hipertenzije.

On deluje putem umanjenja sinteze očne tečnosti (aqueous humor), i povišenja količine izlučivanja iz oka putem uveoskleralnog odliva. Kao tretman za glaukom, on se obično dozira u obliku kapi za oči.

Mehanizam dejstva

Brimonidin je agonist α₂ receptora .

Literatura

Mosby's Drug Guide for Nurses (7th edition; Skidmore) 2007.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

Alphagan P product website
Alphagan P prescribing information Arhivirano 2012-02-10 na Wayback Machine-u

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[5] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[1]

[2]

[3]

[4]

[5]